{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:41:48Z","timestamp":1791463308083,"version":"4.3.4"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.schres.2025.04.033","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T05:38:05Z","timestamp":1747460285000},"page":"180-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Stability of psychotic symptoms and safety in switching to aripiprazole once-monthly according to prior oral antipsychotic drugs"],"prefix":"10.1016","volume":"281","author":[{"given":"Euitae","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom-Woo","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Uk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hee","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Hwa","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Won","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"In Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Joon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Chul","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai Kiu","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Jin","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Soo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.schres.2025.04.033_bb0005","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/schbul\/sbp129","article-title":"Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis","volume":"37","author":"Alvarez-Jimenez","year":"2011","journal-title":"Schizophr. Bull."},{"issue":"1\u20133","key":"10.1016\/j.schres.2025.04.033_bb0010","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.schres.2012.05.007","article-title":"Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies","volume":"139","author":"Alvarez-Jimenez","year":"2012","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2025.04.033_bb0015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1176\/appi.ajp.2013.12050674","article-title":"Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study","volume":"170","author":"Andreasen","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2025.04.033_bb0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-0500-2-6","article-title":"Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia","volume":"2","author":"Ascher-Svanum","year":"2009","journal-title":"BMC. Res. Notes"},{"key":"10.1016\/j.schres.2025.04.033_bb0025","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2025.04.033_bb0030","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/13651501.2023.2231047","article-title":"Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review","volume":"27","author":"Baumann","year":"2023","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"3","key":"10.1016\/j.schres.2025.04.033_bb0035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.rpsm.2016.04.001","article-title":"Adherence predicts symptomatic and psychosocial remission in schizophrenia: naturalistic study of patient integration in the community","volume":"10","author":"Bernardo","year":"2017","journal-title":"Rev. Psiquiatr. Salud Ment."},{"issue":"1","key":"10.1016\/j.schres.2025.04.033_bb0040","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.schres.2025.04.033_bb0045","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"issue":"Suppl. 2","key":"10.1016\/j.schres.2025.04.033_bb0050","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","article-title":"From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics","volume":"25","author":"Correll","year":"2010","journal-title":"Eur. Psychiatry"},{"issue":"Suppl. 3","key":"10.1016\/j.schres.2025.04.033_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.15032su1","article-title":"The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence","volume":"77","author":"Correll","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2025.04.033_bb0060","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/wps.20516","article-title":"What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?","volume":"17","author":"Correll","year":"2018","journal-title":"World Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2025.04.033_bb0065","article-title":"Patient functioning, life engagement, and treatment goals in schizophrenia","volume":"83","author":"Correll","year":"2022","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2025.04.033_bb0070","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2025.04.033_bb0075","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40263-015-0278-3","article-title":"Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism","volume":"29","author":"de Bartolomeis","year":"2015","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.schres.2025.04.033_bb0080","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4088\/JCP.v65n0122b","article-title":"Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism?","volume":"65","author":"DeQuardo","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2025.04.033_bb0085","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.psychres.2016.11.044","article-title":"Clinical trial methodology to assess the efficacy\/effectiveness of long-acting antipsychotics: randomized controlled trials vs naturalistic studies","volume":"247","author":"Fagiolini","year":"2017","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.schres.2025.04.033_bb0090","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.biopsych.2008.07.033","article-title":"A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia","volume":"65","author":"Fleischhacker","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2025.04.033_bb0095","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1017\/S1461145710000490","article-title":"Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial","volume":"13","author":"Fleischhacker","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2025.04.033_bb0100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1192\/bjp.bp.113.134213","article-title":"Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study","volume":"205","author":"Fleischhacker","year":"2014","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2025.04.033_bb0105","series-title":"Abnormal Involuntary Movement Scale (AIMS)","author":"Guy","year":"1976"},{"issue":"13","key":"10.1016\/j.schres.2025.04.033_bb0110","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1080\/14656566.2023.2228686","article-title":"Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches","volume":"24","author":"Hojlund","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"issue":"10202","key":"10.1016\/j.schres.2025.04.033_bb0115","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.schres.2025.04.033_bb0120","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/pcn.12275","article-title":"Psychotropic dose equivalence in Japan","volume":"69","author":"Inada","year":"2015","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"9","key":"10.1016\/j.schres.2025.04.033_bb0125","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2025.04.033_bb0130","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/wps.20060","article-title":"Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies","volume":"12","author":"Kane","year":"2013","journal-title":"World Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2025.04.033_bb0135","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.4088\/JCP.14m09168","article-title":"Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study","volume":"75","author":"Kane","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2025.04.033_bb0140","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2020.2076","article-title":"Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial","volume":"77","author":"Kane","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2025.04.033_bb0145","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1461145703003651","article-title":"Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia","volume":"6","author":"Kasper","year":"2003","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2025.04.033_bb0150","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.schres.2025.04.033_bb0155","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1017\/S1092852916000444","article-title":"Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia","volume":"21","author":"Kim","year":"2016","journal-title":"CNS Spectr."},{"issue":"1","key":"10.1016\/j.schres.2025.04.033_bb0160","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13446","article-title":"Effects of long-acting injectable Paliperidone palmitate on clinical and functional outcomes in patients with schizophrenia based on illness duration","volume":"82","author":"Kim","year":"2021","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2025.04.033_bb0165","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1055\/a-1860-2793","article-title":"Aripiprazole once-monthly versus Oral aripiprazole for schizophrenia in the maintenance phase: a systematic review and network Meta-analysis","volume":"55","author":"Kishi","year":"2022","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1016\/j.schres.2025.04.033_bb0170","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/wps.20632","article-title":"Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons","volume":"18","author":"Kishimoto","year":"2019","journal-title":"World Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2025.04.033_bb0175","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies","volume":"8","author":"Kishimoto","year":"2021","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2025.04.033_bb0180","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1192\/bjp.bp.117.201475","article-title":"Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies","volume":"211","author":"Lally","year":"2017","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2025.04.033_bb0185","doi-asserted-by":"crossref","unstructured":"Leucht, S., Samara, M., Heres, S., Davis, J.M. 2016. Dose equivalents for antipsychotic drugs: the DDD method. Schizophr. Bull. 42 Suppl 1(Suppl 1), S90-94.","DOI":"10.1093\/schbul\/sbv167"},{"key":"10.1016\/j.schres.2025.04.033_bb0190","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.schres.2017.04.013","article-title":"Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study","volume":"192","author":"Naber","year":"2018","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.schres.2025.04.033_bb0195","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1177\/0269881117728428","article-title":"Dopamine supersensitivity psychosis in schizophrenia: concepts and implications in clinical practice","volume":"31","author":"Nakata","year":"2017","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2025.04.033_bb0200","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.psychres.2007.11.012","article-title":"Reliability, validity and ability to detect change of the personal and social performance scale in patients with stable schizophrenia","volume":"161","author":"Nasrallah","year":"2008","journal-title":"Psychiatry Res."},{"issue":"7","key":"10.1016\/j.schres.2025.04.033_bb0205","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4088\/JCP.v69n0702","article-title":"A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine","volume":"69","author":"Newcomer","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2025.04.033_bb0210","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1176\/appi.ajp.2020.20071120","article-title":"Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: a network Meta-analysis","volume":"178","author":"Ostuzzi","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2025.04.033_bb0215","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/wps.20972","article-title":"Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants","volume":"21","author":"Ostuzzi","year":"2022","journal-title":"World Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2025.04.033_bb0220","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s11920-019-1114-0","article-title":"Long-acting injections in schizophrenia: a 3-year update on randomized controlled trials published January 2016-march 2019","volume":"21","author":"Peters","year":"2019","journal-title":"Curr. Psychiatry Rep."},{"issue":"7","key":"10.1016\/j.schres.2025.04.033_bb0225","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2025.04.033_bb0230","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145706006523","article-title":"Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole","volume":"10","author":"Raja","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2025.04.033_bb0235","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004850-200401000-00009","article-title":"Aripiprazole possibly worsens psychosis","volume":"19","author":"Ramaswamy","year":"2004","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.schres.2025.04.033_bb0240","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1176\/appi.ajp.161.7.1308","article-title":"Worsening schizoaffective disorder with aripiprazole","volume":"161","author":"Reeves","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2025.04.033_bb0245","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euroneuro.2005.04.009","article-title":"Size of burden of schizophrenia and psychotic disorders","volume":"15","author":"Rossler","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2025.04.033_bb0250","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/YIC.0000000000000391","article-title":"Case series on aripiprazole and dopamine supersensitivity psychosis","volume":"37","author":"Russell","year":"2022","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2025.04.033_bb0255","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12888-018-1946-x","article-title":"Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study","volume":"18","author":"Schottle","year":"2018","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2025.04.033_bb0260","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12888-020-02488-1","article-title":"The use of long-acting aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index","volume":"20","author":"Schottle","year":"2020","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2025.04.033_bb0265","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.schres.2023.08.026","article-title":"Response prediction in treatment of patients with schizophrenia after switching from oral aripiprazole to aripiprazole once-monthly","volume":"260","author":"Schottle","year":"2023","journal-title":"Schizophr. Res."},{"issue":"9","key":"10.1016\/j.schres.2025.04.033_bb0270","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial","volume":"164","author":"Shim","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2025.04.033_bb0275","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s002130000532","article-title":"Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study","volume":"152","author":"Silvestri","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2025.04.033_bb0280","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.schres.2025.04.033_bb0285","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1038\/s41380-023-02298-3","article-title":"An umbrella review of candidate predictors of response, remission, recovery, and relapse across mental disorders","volume":"28","author":"Solmi","year":"2023","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2025.04.033_bb0290","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.psychres.2011.10.015","article-title":"Impact of symptom resolution on medication adherence in first episode psychosis","volume":"196","author":"Steger","year":"2012","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2025.04.033_bb0295","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.schres.2017.12.010","article-title":"Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia","volume":"197","author":"Taipale","year":"2018","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2025.04.033_bb0300","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0269881115570083","article-title":"Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia","volume":"29","author":"Takase","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2025.04.033_bb0305","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00213-013-3154-1","article-title":"A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder","volume":"228","author":"Takeuchi","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.schres.2025.04.033_bb0310","first-page":"862","article-title":"Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and Meta-analysis","volume":"43","author":"Takeuchi","year":"2017","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2025.04.033_bb0315","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17r11489","article-title":"Can aripiprazole worsen psychosis in schizophrenia? A meta-analysis of double-blind, randomized, controlled trials","volume":"79","author":"Takeuchi","year":"2018","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2025.04.033_bb0320","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41386-018-0278-3","article-title":"Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia","volume":"44","author":"Takeuchi","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"2\u20133","key":"10.1016\/j.schres.2025.04.033_bb0325","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.psychres.2005.05.006","article-title":"Validation of the investigator's assessment questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder","volume":"136","author":"Tandon","year":"2005","journal-title":"Psychiatry Res."},{"issue":"7","key":"10.1016\/j.schres.2025.04.033_bb0330","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a Nationwide cohort of 29\u00a0823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2025.04.033_bb0335","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1176\/appi.ps.55.8.886","article-title":"Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia","volume":"55","author":"Weiden","year":"2004","journal-title":"Psychiatr. Serv."},{"issue":"1","key":"10.1016\/j.schres.2025.04.033_bb0340","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a033315","article-title":"Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort","volume":"24","author":"Wiersma","year":"1998","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2025.04.033_bb0345","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4088\/JCP.v68n0502","article-title":"Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome","volume":"68","author":"Wunderink","year":"2007","journal-title":"J. Clin. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996425001628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996425001628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:04:04Z","timestamp":1774530244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996425001628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":69,"alternative-id":["S0920996425001628"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2025.04.033","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stability of psychotic symptoms and safety in switching to aripiprazole once-monthly according to prior oral antipsychotic drugs","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2025.04.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}